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Nitric oxide (NO) plays an essential role in regulating hypertension and blood flow by inducing relaxation of 
vascular smooth muscle. Male mice deficient in a NO receptor component, the α1 subunit of soluble guanyl-
ate cyclase (sGCα1), are prone to hypertension in some, but not all, mouse strains, suggesting that additional 
genetic factors contribute to the onset of hypertension. Using linkage analyses, we discovered a quantitative 
trait locus (QTL) on chromosome 1 that was linked to mean arterial pressure (MAP) in the context of sGCα1 
deficiency. This region is syntenic with previously identified blood pressure–related QTLs in the human and 
rat genome and contains the genes coding for renin. Hypertension was associated with increased activity of 
the renin-angiotensin-aldosterone system (RAAS). Further, we found that RAAS inhibition normalized MAP 
and improved endothelium-dependent vasorelaxation in sGCα1-deficient mice. These data identify the RAAS 
as a blood pressure–modifying mechanism in a setting of impaired NO/cGMP signaling.
Introduction
Systemic arterial hypertension is one of the most widespread pub-
lic health problems in the developed world and the most prevalent 
modifiable risk factor for cardiovascular disease (CVD) in both 
women and men (1). The pathogenesis of essential hypertension 
is multifactorial, and in the vast majority of cases the etiology of 
hypertension is unknown. Although major advances in the treat-
ment of hypertension have decreased CVD-related deaths over the 
last decade (2), many of the molecular mechanisms underlying the 
development of hypertension remain elusive. Genome-wide asso-
ciation studies (GWAS) suggest that there is a substantial heritable 
component to blood pressure (3, 4). Although GWAS have identi-
fied several loci associated with blood pressure in human beings, 
including loci containing genes that either regulate cGMP levels 
(4–7) or the renin-angiotensin-aldosterone system (RAAS) (8), 
many of the genetic factors determining blood pressure and how 
these factors interact remain to be identified.
Renal abnormalities, such as decreased urinary sodium excretion 
in response to increasing renal perfusion pressure, and increased 
activity of the RAAS are generally considered to be a major contrib-
utor to the development of high blood pressure (9). However, other 
studies support the idea that hypertension can arise from primary 
vascular abnormalities (10, 11). The ability of NO to relax vascular 
smooth muscle and its essential role in the regulation of blood flow 
are well characterized (12, 13). Ample evidence suggests that altered 
NO signaling is involved in the pathogenesis of hypertension (14).
One of the primary receptors for NO is soluble guanylate cyclase 
(sGC), a heme-containing enzyme that generates cGMP. The 
impact of NO on the cardiovascular system is mediated, at least in 
part, by cGMP-dependent mechanisms (15). sGC is a heterodimeric 
enzyme, consisting of α and β subunits. Two isoforms of each sub-
unit have been identified (α1, α2, β1, β2), but only sGCα1β1 and 
sGCα2β1 appear to function in vivo (16). Although the sGCα1β1 
heterodimer is the most abundant sGC isoform in the cardiovas-
culature (17), low levels of cGMP, generated by sGCα2β1, are suffi-
cient to mediate many of NO’s cardiovascular effects (15, 18–20).
The role of sGCα1β1 in regulating blood pressure in humans 
and the importance of sGC as a potential therapeutic target 
for hypertension were recently highlighted in a GWAS identify-
ing a locus that influences blood pressure and that contains the 
genes encoding the sGCα1 and sGCβ1 subunits (7). We previously 
reported that male but not female mice deficient for sGCα1 on 
a 129S6 (S6) background (sGCα1–/–S6) develop hypertension (18). 
These effects appear to be modulated by genetic factors, because 
male sGCα1–/– mice on the C57BL/6 (B6) background (sGCα1–/–B6) 
do not develop hypertension. The underlying pathophysiologi-
cal mechanisms responsible for the differential impact on blood 
pressure of impaired NO/cGMP signaling in these inbred strains 
of mice remained unknown. Therefore, we sought to identify 
genetic determinants critical to the development of hypertension 
in sGCα1–/–S6 mice using an unbiased linkage analysis approach. 
Moreover, we characterized the role of a candidate gene (renin), 
identified in the linkage analysis, in the hypertension associated 
with deficient NO/cGMP signaling.
Results
Identification of a blood pressure quantitative trait locus on chromosome 1, 
and renin as a candidate modifier gene for blood pressure in sGCα1–/– 
mice. As previously described (18, 21), mean arterial blood pres-
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sure (MAP) was higher in male sGCα1–/–S6 mice than in sGCα1–/–B6 
mice (161 ± 2 and 112 ± 3 mmHg, respectively; Figure 1). This 
difference in blood pressure between inbred sGCα1–/– strains con-
firms a strong genetic influence on the regulation of blood pres-
sure in sGCα1–/– mice. To exploit this difference for identification 
of modifier genes of blood pressure, we performed a reciprocal 
F1 intercross between sGCα1–/–B6 and sGCα1–/–S6 mice. sGCα1–/–F2 
progeny exhibited a large variance in MAP, ranging from values 
observed in sGCα1–/–B6 to values observed in sGCα1–/–S6 mice, 
demonstrating that the hypertension associated with sGCα1 defi-
ciency is preserved in a subset of mice in the F2 cross (Figure 1). 
Using the phenotypic variance in genetically homogeneous paren-
tal and F1 mice as an estimate of the trait’s variation from envi-
ronmental influences and the phenotypic variance in F2 mice as 
an estimate of the trait’s variation from both genetic and environ-
mental influences, we estimated the broad heritability of the trait 
to be greater than 0.5.
A linkage analysis in a first cohort of 92 F2 mice, using 120 
genome-wide SNPs, identified a quantitative trait locus (QTL) on 
chromosome 1 that influences 
blood pressure (lod score, 3.0; 
Supplemental Figure 1; supple-
mental material available online 
with this article; doi:10.1172/
JCI60119DS1). Genotyping of a 
second independent cohort of 96 
additional F2 mice yielded a col-
lective lod score of 5.3 at the chro-
mosome 1 locus (genome-wide 
corrected, P = 0.006; Supplemen-
tal Figures 2 and 3). To refine the 
linkage peak through additional 
recombinants and higher marker 
density, the original 188 mice and 
a third independent cohort of 96 
F2 mice were genotyped for 28 
SNPs across the QTL on chromo-
some 1. Linkage at this locus was 
highly significant, with a final 
lod score of 6.3 (genome-wide 
corrected, P = 0.0006) (Figure 2). 
We designated this locus Hsgcq 
(hypertension associated with sGCα1-deficiency QTL). Two other 
loci of interest were identified, on chromosomes 4 and 9, with 
maximal lod scores of 3.6 and 3.9, respectively. Here, we focused 
on the locus (Hsgcq) with the highest lod score.
Hsgcq was localized to a position close to Mm37-1-130689858 
(Figure 2). The 1.5 lod confidence interval spanned a region on 
chromosome 1 between Mm37-1-119319789 and Mm37-1-
158911588. One of the genes in this region is renin 1 (position on 
chromosome 1: 135,247,143–135,256,900), a candidate modifier 
gene of hypertension (22). Mice on the B6 background have one 
renin gene (renin 1c), whereas mice on the S6 background have 
two renin genes, designated renin 1d and renin 2 (23–25). In addi-
tion, when comparing the genomic DNA sequence of renin 1c and 
renin 1d (~10,000 bp), we identified 201 nucleotide substitutions 
and 126 nucleotide insertions or deletions, resulting in a sequence 
variability of 3.3%. We identified 21 nucleotides that were different 
between renin 1c and renin 1d cDNA (1,592 bp for both; Supple-
mental Figure 4). On the protein level, we identified 5 amino acid 
differences (of 402 amino acids): R58W, I68T, V160S, D315E, and 
Y352N (Supplemental Figure 5).
Renal renin 1 gene expression, assessed using quantitative RT-
PCR (qRT-PCR), was similar in B6 mice and in S6 mice of either 
genotype (Figure 3A). No difference was observed in renal renin 
2 mRNA levels between sGCα1–/–S6 and wild-type mice on the S6 
background (WTS6; Figure 3B). qRT-PCR confirmed the absence of 
renin 2 expression in both sGCα1–/–B6 and WTB6 mice (Figure 3B).
To evaluate the impact of the renin genotype on blood pres-
sure, we grouped sGCα1–/–F2 mice according to their renin geno-
type. Seventy-six mice were homozygous for renin 1c, 73 mice 
were homozygous for renin 1d and renin 2, and 135 mice were 
heterozygous. Presence of the renin 1d and renin 2 genes was asso-
ciated with increased blood pressure in a dominant manner: while 
MAP was 139 ± 2 mmHg in mice homozygous for renin 1c, MAP 
was 150 ± 2 and 152 ± 2 mmHg in mice that were heterozygous 
and homozygous, respectively, for renin 1d and renin 2 (Figure 4). 
These findings confirm that renin 1d, renin 2, or a closely linked 
gene functions as a dominant modifier gene for blood pressure in 
Figure 1
Genetic background affects blood pressure in sGCα1–/– mice. MAP 
measured invasively in anesthetized male sGCα1–/–F2 mice (n = 284 
mice) lies between MAP observed in male sGCα1–/–B6 and sGCα1–/–S6 
mice (n = 11 and 20, respectively). *P < 0.001 versus all other groups 
by 1-way ANOVA.
Figure 2
Identification of a locus on chromosome 1 that modifies blood pressure in sGCα1–/– mice. Chromosome 1 
fine mapping for blood pressure, performed using 28 SNPs in 284 male sGCα1–/–F2 (sGCα1–/–S6 × 
sGCα1–/–B6) progeny. The SNP markers are plotted on the x axis, spaced according to cross-derived 
recombination distances. The y axis represents the lod scores. A highly significant lod score of 6.3 
(P = 0.0006) was obtained at Mm37-1-130689858 (marked by a vertical line). The 95% confidence inter-
val (1.5 lod) is flanked by vertical dashed lines.
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sGCα1–/– mice and suggest that the effect size of Hsgcq on blood 
pressure is approximately 11 mmHg.
The strain-specific hypertension in sGCα1–/– mice is associated with 
increased activity of the RAAS. To test whether the genetic back-
ground affected the RAAS, we measured plasma Ang II and plasma 
aldosterone levels in male WTB6, sGCα1–/–B6, WTS6, and sGCα1–/–S6 
mice. Plasma Ang II levels were similar in WT and sGCα1–/– mice 
on either the B6 or S6 background but were higher in S6 mice than 
in B6 mice (Figure 5A), confirming the existence of strain-specific 
differences in the RAAS. Plasma aldosterone levels did not differ 
in WTB6 and sGCα1–/–B6 mice (Figure 5B). However, plasma aldo-
sterone levels were greater in sGCα1–/–S6 than in WTS6 mice (Figure 
5B). Expression levels of aldosterone synthase (cytochrome P450, 
family 11, subfamily b, polypeptide 2, or CYP11B2) in adrenal 
glands did not differ between sGCα1–/–B6 and WTB6 mice but were 
higher in sGCα1–/–S6 than in WTS6 mice (Supplemental Figure 6). 
Consistent with the observed hyperaldosteronism, plasma K+ lev-
els were lower and Na+ levels were higher in sGCα1–/–S6 mice than 
in WTS6 mice (Table 1).
To further determine the contribution of the increased activ-
ity of the RAAS to the elevated blood pressure associated with 
sGCα1 deficiency, we treated male WTS6 and sGCα1–/–S6 mice with 
the clinically used renin inhibitor aliskiren, which is available for 
oral administration. Aliskiren did not alter blood pressure in male 
WTS6 mice but normalized blood pressure in male sGCα1–/–S6 mice 
(Figure 6A). Similarly, the aldosterone antagonist spironolactone 
did not alter blood pressure in male WTS6 mice but normalized 
blood pressure in male sGCα1–/–S6 mice (Figure 6B). No change 
in blood pressure was detected in either WTB6 or sGCα1–/–B6 mice 
treated with the same dose of spironolactone (Supplemental Fig-
ure 7). Furthermore, the Ang II type 1 receptor (AT1) antagonist 
losartan decreased blood pressure more in male sGCα1–/–S6 mice 
than in WTS6 mice (Supplemental Figure 8). Together, these data 
suggest that increased activity of the RAAS contributes to the 
hypertension associated with sGCα1 deficiency in S6 mice.
Normal glomerular filtration rate but decreased K+-excretion in sGCα1–/– 
mice. To test whether increased RAAS activity resulted in hyperten-
sion via an effect on renal function, we performed renal clearance 
studies in male WTS6 and sGCα1–/–S6 mice. While absolute (ENa) 
and fractional (FENa) urinary sodium excretion were similar in 
sGCα1–/–S6 mice and in WTS6 mice, absolute (EK) and fractional 
(FEK) urinary potassium excretion were lower in sGCα1–/–S6 mice 
than in WTS6 mice. However, urinary volume and glomerular fil-
tration rate (GFR), both corrected for body weight, were similar 
in WTS6 and sGCα1–/–S6 mice (Table 1). The lower body weight 
in sGCα1–/–S6 mice compared with WTS6 mice may be secondary 
to the mild gastrointestinal dysfunction observed in sGCα1–/–S6 
mice (26). Together with the observation that blood urea nitrogen 
(BUN) levels were not higher in sGCα1–/–S6 mice than in WTS6 mice, 
these findings argue against a central role for renal dysfunction in 
the hypertension observed in sGCα1–/–S6 mice.
Activity of the RAAS modulates endothelium-dependent vascular reactiv-
ity. We previously reported that vascular smooth muscle relaxation 
in response to endothelium-derived NO was severely attenuated in 
aortic and femoral rings isolated from sGCα1–/–S6 mice (19). In an 
independent study, the ability of acetylcholine to induce vasorelax-
ation in isolated carotid arteries was attenuated in sGCα1–/–B6 mice 
(27). In the current study, we tested the hypothesis that differenc-
es in vascular reactivity between sGCα1–/– mice on the B6 and S6 
backgrounds contribute to the observed strain-related difference 
Figure 3
S6 mice express two renin isoforms, while B6 mice express one 
renin isoform. mRNAs encoding renin 1 (A) and renin 2 (B) were 
measured via qRT-PCR in kidneys of male WT and sGCα1–/– mice 
on the S6 or B6 genetic background. n = 10–15/group. No significant 
differences in renin 1 mRNA levels were found between WT and 
sGCα1–/– mice on either background. mRNA levels of renin 2 were 
similar in WT and sGCα1–/– mice on the S6 genetic background, 
and were undetectable in WT and sGCα1–/– mice on the B6 genetic 
background. *P < 0.001 versus S6.
Figure 4
Mice homozygous or heterozygous for the 129S6 renin locus have 
higher blood pressure than mice homozygous for the B6 renin locus. 
MAP was measured invasively in anesthetized male sGCα1–/–F2 mice 
homozygous for renin 1c (Ren1c/Ren1c = the B6 locus, n = 76), homo-
zygous for renin 1d/renin 2 (Ren1d-Ren2/Ren1d-Ren2 = the S6 locus, 
n = 73), or heterozygous for both loci (Ren1c/Ren1d-Ren2; n = 135). 
*P < 0.001 versus all other groups by 1-way ANOVA.
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in blood pressure. We compared vascular relaxation in response 
to acetylcholine in isolated pre-constricted aortic rings from male 
WT and sGCα1–/– mice on both the B6 and S6 backgrounds. Ace-
tylcholine-induced vascular relaxation was impaired to a greater 
extent in sGCα1–/–S6 than in sGCα1–/–B6 mice (Figure 7). A similar 
result was obtained in mesenteric arteries (Supplemental Figure 9). 
These findings suggest that the decreased sensitivity of the vascu-
lature to endothelium-dependent relaxation may contribute to the 
strain-specific hypertension in sGCα1–/– mice.
To investigate whether increased RAAS signaling in sGCα1–/–S6 
mice reduces the ability of the vasculature to vasorelax, we studied 
the responsiveness to acetylcholine of aortic rings isolated from 
mice treated for 3 weeks with the angiotensin-converting enzyme 
(ACE) inhibitor enalapril. Importantly, after prolonged inhibi-
tion of RAAS signaling with enalapril, the ability of acetylcholine 
to relax aortic rings isolated from sGCα1–/–S6 mice no longer dif-
fered from that observed in aortic rings isolated from sGCα1–/–B6 
mice (Figure 7). Treatment with enalapril also tended to improve 
the ability of acetylcholine to induce vasorelaxation in sGCα1–/–B6 
mice (P = 0.069 vs. sGCα1–/–B6 mice that did not receive enalapril). 
Taken together, these results suggest that activity of the RAAS 
has a direct impact on endothelium-dependent vasorelaxation. 
Increased RAAS activity may therefore be, at least in part, responsi-
ble for the greater impairment of vascular relaxation in sGCα1–/–S6 
than in sGCα1–/–B6 mice, thereby contributing to the hypertension 
observed in sGCα1–/–S6 mice.
Discussion
Animal and epidemiological studies have demonstrated that 
genetic factors contribute to the pathogenesis of essential hyper-
tension. Recent advances in performing and interpreting GWAS 
and candidate gene–association studies have allowed the identifi-
cation of common genetic variants that influence blood pressure 
(3, 5–8, 28). Genetic variation in both cGMP signaling, including 
in the genes encoding the sGCα1 β1 isoform (7), and RAAS signal-
ing pathways have been implicated in the regulation of blood pres-
sure in both human (5–8) and animal (29–32) models of hyperten-
sion. Here, we used both a nonbiased genetic approach (linkage 
analysis) and a targeted approach (investigating a specific molecu-
lar pathway, i.e., RAAS) to identify renin as a candidate modifier 
gene for blood pressure in a setting of impaired NO/cGMP signal-
ing. In addition, our findings suggest that a vascular, rather than a 
renal, effect of increased RAAS activity underlies the hypertension 
observed in sGCα1–/–S6 mice.
Variation in the genetic makeup of laboratory mouse strains 
affects the cardiovascular phenotype of those strains (33, 34). For 
example, ACE2 deficiency was associated with a modest increase 
in blood pressure in mice on the B6 background but had no effect 
on blood pressure in S6 mice (35). Inhibition of NO synthase had 
Table 1
Renal function is similar in WTS6 and sGCα1–/–S6 mice
 WT sGCα1–/– P value
Renal clearance studies
n 8 12 
Age (wk) 35 ± 1 36 ± 1 0.1405
BW (g) 35 ± 1 28 ± 1 0.0001
UV/BW (μl/min/100 g) 3.6 ± 0.4 3.2 ± 0.3 0.3316
GFR/BW (ml/min/100 g) 0.68 ± 0.08 0.70 ± 0.06 0.8762
ENa (μEq/min/100 g BW) 0.69 ± 0.12 0.58 ± 0.06 0.4036
EK (μEq/min/100 g BW) 0.55 ± 0.07 0.31 ± 0.05 0.0086
FENa (%) 0.72 ± 0.14 0.60 ± 0.05 0.3451
FEK (%) 19 ± 2 12 ± 2 0.0316
UNa (μEq) 193 ± 27 188 ± 12 0.8303
UK (μEq) 162 ± 18 107 ± 17 0.0432
MAP (mmHg) 127 ± 3 145 ± 3 0.0005
Blood analysis
n 15 13 
Age (wk) 10 ± 1 10 ± 1 0.8910
BW (g) 27 ± 1 22 ± 1 0.0007
PNA (mmol/l) 144 ± 0 146 ± 1 0.0201
PK (mmol/l) 5 ± 1 4 ± 1 0.0035
BUN (mg/dl) 33 ± 5 26 ± 5 0.0003
Values are mean ± SEM. UV, urinary volume; UNa, urinary sodium con-
centration; UK, urinary potassium concentration; PNa, plasma sodium 
concentration; PK, plasma potassium concentration. Absolute P values 
from Student’s t test are shown.
Figure 5
Activity of the RAAS is increased in sGCα1–/– mice on the S6 back-
ground. (A) Ang II in plasma of male WT and sGCα1–/– mice on the B6 
and on the S6 genetic background. n = 6–9. P < 0.01 for S6 versus 
B6 by 2-way ANOVA. (B) Plasma aldosterone levels in male WT and 
sGCα1–/– mice on the B6 and on the S6 genetic background. n = 11 for 
all groups. *P < 0.05 versus WTS6 by 2-way ANOVA.
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a more profound effect on renal blood flow in S6 mice than in B6 
mice (36), blood pressure was consistently higher in S6 than in 
B6 mice (36), and S6 mice were found to be more susceptible to 
the development of hypertension and kidney injury after subtotal 
nephrectomy than were B6 mice (37). Several reports demonstrat-
ed that linkage studies in rodents represent a feasible and powerful 
approach to identify genetic loci and/or candidate modifier genes 
involved in the etiology of hypertension (31, 37–40). In the current 
study, we sought to identify genetic variants that modify blood 
pressure in sGCα1–/– mice by taking advantage of the observation 
that male sGCα1–/–S6 but not sGCα1–/–B6 mice develop hypertension 
(18, 21). Using a linkage analysis approach in 284 sGCα1–/–F2 mice, 
we identified a genomic locus (Hsgcq) on chromosome 1 (covering 
≈40 Mb) that was associated with hypertension in sGCα1–/– mice. 
This QTL (located on Mus musculus 1-E4) is syntenic to known 
hypertension QTLs in rats (Rattus norvegicus 13q13) and humans 
(Homo sapiens 1q32; Supplemental Figure 10). Importantly, vari-
ants of one of the genes located in this region, renin, were previ-
ously identified to be associated with blood pressure in rats (41, 
42) and humans (43, 44). Additional research will be required to 
identify other blood pressure–modifying genes that contribute to 
the hypertension in sGCα1–/–S6 mice (e.g., in the other loci identi-
fied in our linkage analysis [on chromosomes 4 and 9]).
In the Hsgcq QTL identified in our linkage study, renin repre-
sents a strong biological candidate modifier gene of blood pres-
sure. Renin is a key enzyme in the RAAS that is responsible for the 
control of fluid homeostasis and blood pressure. It is well estab-
lished that inappropriate activation of the RAAS is an important 
contributor to the pathogenesis of hypertension (45). Importantly, 
genetic linkage of the renin locus with hypertension was previ-
ously identified in large population studies (44). Human and rat 
genomes contain a single gene for renin. Mice, however, display 
two alternative genotypes at the renin locus, with some inbred 
mouse strains (e.g., B6) having only a single renin gene designated 
renin 1c, while others (e.g., S6) possess two closely linked renin 
genes on chromosome 1 termed renin 1d and renin 2 (23–25). 
Overexpression of murine renin 2 in rats resulted in hyperten-
sion (46) that was attributed to RAAS-dependent blunting of NO/
sGC–mediated vasorelaxation (47). In addition to the previously 
reported duplication of the renin gene in S6 mice, multiple genetic 
differences were identified between renin 1c and renin 1d, includ-
ing 5 missense mutations. Whether the duplication and/or the 
renin 1 missense mutations contribute to the strain-specific and 
RAAS-dependent hypertension in sGCα1–/–S6 mice remains to be 
determined. It is well known that the mechanism of activation of 
pro-renin is species-specific (48) and that the active site of human 
renin is unique (49). Based on the extensive differences in genom-
ic, cDNA, and amino acid sequence between the murine and 
human renin 1 genes (see Supplemental Figure 11 for the amino 
acid alignment between human renin 1 and mouse renin 1c), it is 
Figure 6
RAAS inhibition normalizes blood pressure in sGCα1–/–S6 mice. (A) 
MAP, measured invasively in anesthetized male WT and sGCα1–/– 
mice on the 129S6 background treated with vehicle (n = 8 and 6, 
respectively) or aliskiren (n = 5 and 8, respectively). *P < 0.001 ver-
sus WT vehicle; †P < 0.001 versus sGCα1–/– vehicle. (B) MAP in male 
WT and sGCα1–/– mice on the 129S6 background treated with vehicle 
(n = 5 and 8, respectively) or spironolactone (n = 5 and 12, respective-
ly). *P < 0.01 versus WT vehicle; †P < 0.001 versus sGCα1–/– vehicle.
Figure 7
The strain-specific hypertension in sGCα1–/– mice is associated with 
greater impairment of vascular reactivity in sGCα1–/–S6 mice than in 
sGCα1–/–B6 mice. Acetylcholine-induced relaxation was studied in 
phenylephrine-precontracted aortic rings from male wild-type (black 
symbols, solid line) and sGCα1-deficient mice (sGCα1–/–) on a B6 (cir-
cles) or S6 (squares) genetic background. sGCα1–/– mice were either 
pretreated (gray symbols, dashed line) or not (white symbols, dotted 
line) with the ACE inhibitor (ACEI) enalapril. Acetylcholine-induced 
vascular relaxation was impaired to a greater extent in sGCα1–/–S6 than 
in sGCα1–/–B6 mice. In vivo pretreatment with enalapril restored vas-
cular reactivity in sGCα1–/–S6 to levels observed in sGCα1–/–B6 mice. 
n = 9, 8, 9, 4, 10, and 12 for sGCα1–/–S6, sGCα1–/–B6, sGCα1–/–S6ACEI, 
sGCα1–/–B6 ACEI, WTS6, and WTB6, respectively. *P < 0.001 versus 
sGCα1–/–S6; †P < 0.01 versus sGCα1–/–B6; ‡P < 0.05 versus sGCα1–/–S6; 
§P < 0.01 versus sGCα1–/–S6.
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unlikely that identification of the causative mutation (or muta-
tions) in the murine renin genes would be directly translatable to 
the human renin gene. However, the finding that the combina-
tion of altered RAAS signaling (regardless of the causative muta-
tion) and impaired NO/cGMP signaling results in hypertension in 
mice is translatable to the human condition. Both increased RAAS 
activity (45) and impaired NO/cGMP signaling (associated with, 
for example, endothelial dysfunction [ref. 50] and oxidation of 
sGC [ref. 51]) can increase blood pressure in humans. Genetic vari-
ants in the renin gene (43, 44) and in a locus encoding the sGCα1 
and sGCβ1 subunits (7) were found to be associated with blood 
pressure, highlighting the relevance of renin and sGC in regulating 
blood pressure in humans.
To confirm that renin is a modifier for blood pressure in a set-
ting of impaired NO/cGMP signaling, we compared the activity of 
the RAAS in S6 and B6 mice. The observation that plasma Ang II 
levels were higher in S6 mice than in B6 mice confirms the exis-
tence of strain-specific differences in activity of the RAAS. It is 
likely that the observation that Ang II levels were higher in S6 than 
in B6 mice, regardless of their sGCα1 genotype, is a consequence of 
the difference in renin genotype, and that renin acts as a modifier 
of blood pressure in both sGCα1–/– and WT mice. Although blood 
pressures were higher in WTS6 and sGCα1–/–S6 mice (expressing 
renin 1d and renin 2) than in WTB6 and sGCα1–/–B6 mice (express-
ing renin 1c), respectively, our results suggest that the blood pres-
sure–modifying effect of renin is more apparent when NO/cGMP 
signaling is impaired (e.g., in sGCα1–/– mice) than when NO/cGMP 
signaling is intact (e.g., in WT mice).
Plasma aldosterone and adrenal expression of the aldosterone 
synthase CYP11B2 were higher in hypertensive sGCα1–/–S6 mice 
than in normotensive WTS6 mice. This was an unexpected finding, 
since an increase in blood pressure would be expected to lead to a 
homeostatic reduction in RAAS activity due to the renal barorecep-
tor mechanism (52). It is important to note that a higher adrenal 
expression level of CYP11B2 in sGCα1–/–S6 than in WTS6 mice does 
not provide additional evidence that renin is a modifier gene for 
blood pressure in sGCα1–/–S6 mice, nor does it indicate that Cyp11b2 
(located on chromosome 15qD3) is a modifier gene. Instead, higher 
adrenal CYP11B2 expression levels in sGCα1–/–S6 than in WTS6 mice 
suggest that NO/cGMP signaling modulates RAAS activity at the 
level of Cyp11b2 gene expression. Furthermore, increased adrenal 
CYP11B2 expression levels likely contribute to the elevated plasma 
aldosterone levels observed in sGCα1–/–S6 mice.
Blocking the RAAS, by inhibiting renin activity with aliskiren 
or aldosterone receptor signaling with spironolactone, at doses 
that did not affect blood pressure in WT mice and sGCα1–/–B6 
mice, normalized blood pressure in sGCα1–/–S6 mice. Furthermore, 
acute administration of the AT1 antagonist losartan decreased 
blood pressure to a greater extent in sGCα1–/–S6 mice than in WTS6 
mice. The greater sensitivity of sGCα1–/–S6 mice to the blood pres-
sure-lowering effects of aliskiren, spironolactone, and losartan 
suggests that increased activity of the RAAS contributes to the 
hypertension associated with sGCα1 deficiency in S6 mice. It is 
conceivable that both genetics (renin genotype) and interactions 
between the NO/cGMP signaling and the RAAS (altered gene 
expression of Cyp11b2) contribute to the hypertension observed 
in sGCα1–/–S6 mice. Additional characterization of the RAAS, both 
renal and extrarenal, is required to fundamentally understand the 
role of altered RAAS signaling in the hypertension associated with 
impaired NO/cGMP signaling.
Many studies have established an important role for the kidney 
in the development of high blood pressure (9). We did not find evi-
dence of overt renal dysfunction in hypertensive sGCα1–/–S6 mice. 
BUN levels were not increased in sGCα1–/–S6 mice, and GFR was 
similar in WTS6 and sGCα1–/–S6 mice. The mechanisms underlying 
the lower absolute and fractional urinary potassium excretion in 
sGCα1–/–S6 mice than in WTS6 mice remain to be determined. As 
would be expected, higher plasma aldosterone levels in sGCα1–/–S6 
than in WTS6 mice were associated with lower plasma K+ levels 
and higher plasma Na+ levels in the former. It is possible that kid-
neys in sGCα1–/–S6 mice adapt to decreased K+ levels by increas-
ing reabsorption and/or reducing secretion of K+ in an attempt 
to maintain homeostasis. Alternatively, the lower K+ excretion in 
sGCα1–/–S6 than in WTS6 mice may be due to reduced K+ channel 
activity in the kidneys of sGCα1–/–S6 mice. The latter hypothesis 
stems from the observation that NO and cGMP can stimulate the 
activity of apical small-conductance K+ (SK+) and basolateral K+ 
channels, respectively (53, 54). Finally, we cannot exclude the pos-
sibility that reduced K+ levels and excretion are attributable to gas-
trointestinal malabsorption, caused by abnormal gastric motility 
previously observed in sGCα1–/–S6 mice (26).
In the absence of apparent renal dysfunction, hypertension was 
previously reported to arise from primary vascular abnormali-
ties (10). In cGMP-dependent protein kinase 1α mutant mice, for 
example, hypertension was observed in the setting of normal renal 
function and normal renal salt handing, but decreased vascular 
relaxation in response to a nitrovasodilator (11). We previously 
reported that both endothelium-dependent and endothelium-
independent vascular relaxation are attenuated in aortic and femo-
ral artery rings isolated from sGCα1–/–S6 mice (19) and in carotid 
arteries isolated from sGCα1–/–B6 mice (27). These findings high-
lighted the importance of sGCα1β1-derived cGMP in the relax-
ation of vascular smooth muscle by NO. In the current study, we 
observed that the ability of acetylcholine to induce vasorelaxation 
is impaired to a greater extent in sGCα1–/–S6 than in sGCα1–/–B6 
mice, both in the aorta and in mesenteric arteries, suggesting that 
decreased vascular reactivity may contribute to the strain-specific 
hypertension in sGCα1–/– mice. Similarly, greater impairment of 
endothelium-dependent relaxation in WTS6 mice than in WTB6 
may contribute to the higher blood pressure observed in WTS6 
mice than in WTB6 mice (36).
Surprisingly, in vivo inhibition of RAAS signaling with the ACE 
inhibitor enalapril restored vascular reactivity in sGCα1–/–S6 mice 
to the level observed in sGCα1–/–B6 mice that were either pretreated 
with enalapril or not pretreated with enalapril. Together, these 
results suggest that differences in RAAS activity can impact the 
ability of the vasculature to relax in response to acetylcholine and 
raise the possibility that Hsgcq influences blood pressure in the 
context of sGCα-deficiency by directly modulating endothelium-
dependent vasorelaxation. To unequivocally demonstrate that 
Hsgcq modulates the ability of acetylcholine to induce vascular 
relaxation, vascular reactivity needs to be assessed in arteries iso-
lated from sGCα1–/–F2 mice.
Multiple studies have demonstrated that extrarenal (including 
vascular) RAAS signaling can modulate blood pressure (55, 56). 
Renin (57), aldosterone (58), and aldosterone receptors (59) were 
previously shown to be expressed in vascular tissue (60). In addi-
tion, aldosterone itself was reported to have a direct vasoconstric-
tive effect (61, 62). However, the exact function of the vascular 
RAAS remains elusive (60). Our model of RAAS-dependent hyper-
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tension associated with sGCα1 deficiency may allow for further 
elucidation of the role of the vascular RAAS in regulation of vas-
cular tone. One potential mechanism by which increased RAAS 
signaling may affect vascular function is an aldosterone-mediated 
increase in oxidative stress (55). The resulting oxidative modifica-
tion of the Cys122 residue on sGCβ1 would convert sGCα2β1 in 
sGCα1–/– mice to an NO-insensitive state (55). Activity of sGCα2β1 
was previously shown to contribute to the vasorelaxing effect of 
NO (15, 18, 19). Decreased activity of sGCα2β1 would further dis-
rupt normal vasodilatory signaling in vascular smooth muscle. 
However, whether increased activity of the RAAS associated with 
sGCα1 deficiency results in subsequent oxidation and inactiva-
tion of sGCα2β1 remains to be determined. Additional studies are 
required to test whether NO-independent sGC activators that can 
activate oxidized sGC (63, 64) are able to rescue the vascular dys-
function seen in sGCα1–/–S6 mice.
We previously reported that hypertension in sGCα1–/–S6 mice was 
male specific and testosterone dependent (18). It is conceivable 
that androgens modulate RAAS activity, thereby affecting blood 
pressure in a sex-specific manner and contributing to the hyper-
tension observed in sGCα1–/–S6 mice (65). For example, renin 2 was 
reported to be an androgen-responsive gene (66, 67). Moreover, 
overexpression of murine renin 2 in rats resulted in testosterone-
dependent hypertension (68). Furthermore, the RAAS has been 
suggested to have a greater impact on blood pressure regulation 
in males than in females: knocking out the gene encoding ACE1 
decreased blood pressure in male but not female mice (69), and in 
a large population study, genetic linkage of the ACE locus with 
hypertension was found in men but not in women (70). Precisely 
how testosterone interacts with the RAAS to modulate blood pres-
sure in sGCα1–/–S6 mice remains to be investigated.
Associations between common gene variants and hypertension 
offer mechanistic insights into the regulation of blood pressure and 
may help in the development of novel intervention strategies to pre-
vent and treat CVD. Improved knowledge of interactions between 
signaling pathways previously identified to regulate blood pressure 
will impact our understanding of the etiology of essential hyper-
tension. For example, the observation that increased activity of the 
RAAS contributes to the pathogenesis of hypertension associated 
with impaired NO/cGMP signaling may have clinical implications. 
Both impaired NO/cGMP signaling (14, 15, 18) and increased activ-
ity of the RAAS (9) were reported to be involved in the development 
of hypertension. Therefore, a combination of pharmacological 
inhibition of the RAAS and pharmacological stimulation of sGC 
may offer novel strategies to treat hypertension (71, 72), especially 
in settings where use of classical NO donor compounds is problem-
atic because of the development of tolerance (73).
In conclusion, the identification of a locus on mouse chromo-
some 1 that contains the renin gene(s) and that modifies blood 
pressure in sGCα1–/– mice, together with the observation that the 
strain-specific hypertension in sGCα1–/– mice is associated with 
increased activity of the RAAS, strongly suggests that activity of 
the RAAS modulates the susceptibility to hypertension in a setting 
of impaired NO/cGMP signaling. The finding that NO/cGMP sig-
naling and RAAS signaling (two established pathways in the regu-
lation of blood pressure in humans) interact, has great potential to 
advance our understanding of the etiology of human hypertension. 
Understanding the interaction of pathways that modulate blood 
pressure is particularly critical, given the multigenic pathogenesis 
of most forms of hypertension, and may help define genetically 
distinct subgroups of men and women with essential hyperten-
sion. Further elucidation of how interaction of NO/cGMP signal-
ing and the RAAS affects cardiovascular function in mice is likely 
to impact the clinical development of sGC-activating compounds 
for treatment of CVDs (51) and may promote the search for new 
sGC isoform–specific agonists.
Methods
Generation and blood pressure measurement of F2 offspring from an sGCα1–/–S6 × 
sGCα1–/–B6 intercross. Only male mice were studied. Generation of sGCα1–/–S6 
(generated on the S6 background) and sGCα1–/–B6 mice (backcrossed 8 gen-
erations with B6 mice from The Jackson Laboratory) was described previ-
ously (18, 21). WTB6 and WTS6 mice were purchased from The Jackson Lab-
oratory and Taconic, respectively. Male sGCα1–/–S6 and female sGCα1–/–B6 
mice (4 breeding pairs) were crossed to yield F1 offspring. The F1 offspring 
were subsequently intercrossed (16 breeding pairs) to yield F2 offspring. 
MAP was measured invasively in 284 male F2 offspring at 4 months of age, 
as previously described (18, 21). Briefly, mice were anesthetized by i.p. injec-
tion with ketamine (100 mg/kg), fentanyl (50 mg/kg), and pancuronium 
(2 mg/kg); intubated; and mechanically ventilated (FiO2 of 1, 10 μl/g, 
120 breaths per minute). A fluid-filled catheter was inserted into the left 
carotid artery for infusion of saline solution (2 ml/h) and for measure-
ment of MAP. The reproducibility of the invasive hemodynamic technique 
described here was validated previously by measuring blood pressure in 
WTS6 and sGCα1–/–S6 mice using radiotelemetry (in unrestrained, unanes-
thetized mice), invasive hemodynamics (in anesthetized mice), and tail-cuff 
(in restrained, unanesthetized mice) (18).
Genotyping. Genomic DNA was isolated from ear tissue of 284 sGCα1–/–F2 
mice using a commercially available kit (DNeasy, QIAGEN). For genome 
scans, mice were genotyped using 120 B6-S6 informative SNPs covering 
the murine autosomes (average inter-marker spacing, 22.2 Mb; largest 
inter-marker gap, 54.6 Mb). All SNPs were assayed using Sequenom Mas-
sARRAY iPLEX GOLD chemistry. Oligonucleotides were synthesized and 
subjected to quality control analysis by mass spectrometry at Integrated 
DNA Technologies. All SNPs were genotyped in multiplexed pools of up 
to 36 assays, designed by AssayDesigner v.3.1 software, starting with 10 ng 
DNA per pool. Seven nanoliters of reaction were loaded onto each posi-
tion of a 384-well SpectroCHIP preloaded with 7 nl matrix (3-hydroxy-
picolinic acid). SpectroCHIPs were analyzed in automated mode by a 
MassArray MALDI-TOF Compact System 2 with a solid phase laser mass 
spectrometer (Bruker Daltonics). Variants were called by real-time Spec-
troCALLER algorithm and analyzed by SpectroTYPER v.4.0 software, and 
clusters were manually reviewed for validation of genotype calls. Poorly 
genotyped markers were removed prior to analysis. Subsequently, all 284 
sGCα1–/–F2 mice were genotyped using 28 SNPs spaced approximately 
4 Mb apart and spanning a region on chromosome 1 extending from 
30 Mb to 173 Mb. Reported genetic map positions for the markers were 
retrieved from the SNP database (build 36.1) of the National Center for 
Biotechnology Information (NCBI).
Linkage and sequence analysis. As the phenotype appears normally distrib-
uted, parametric linkage analysis was performed using MAPMAKER/QTL 
(74) to identify QTLs associated with blood pressure. For an F2 intercross, 
a lod of approximately 2.8 is considered “suggestive” (expected to be seen 
by chance once per genome scan), a lod of approximately 4.3 is considered 
“significant” (with a genome-wide corrected P = 0.05, a score expected to 
be seen by chance only once per 20 genome scans), and a lod of approxi-
mately 6.1 is considered “highly significant” (genome-wide corrected 
P = 0.001) (75). A region within 1.5 lod score units of the maximum 
lod was used to represent the 95% interval for a strong QTL (76). The 
genome-wide scans were plotted with the use of the J/qtl mapping pro-
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gram (version 0.8) (http://churchill.jax.org/software/jqtl.shtml). Heri-
tability was calculated as (F2 variance — weighted average of parental 
variance and F1 variance)/F2 variance. Genomic, cDNA, and amino acid 
sequences for the B6 and S6 renin loci were obtained from publicly avail-
able databases (ENSEMBL and NCBI, respectively) and were aligned 
using MegAlign software (DNASTAR).
Measurement of gene expression. Total RNA was extracted from whole kid-
neys or adrenal glands harvested from 8- to 16-week-old mice using TRIzol 
reagent (Invitrogen), and cDNA was synthesized using Maloney’s murine 
leukemia virus reverse transcriptase (Promega). Renin 1c, renin 1d, renin 2, 
CYP11B2, and 18S rRNA transcript levels were measured by real-time PCR 
using the SYBR or TaqMan universal PCR master mix (Applied Biosys-
tems) in a Mastercycler ep realplex 2 (Eppendorf). Primers were designed 
for renin 1 (detecting renin 1c and renin 1d; 5′-CTCTCTGGGCACTCTT-
GTTGC-3′ and 5′-GGGAGGTAAGATTGGTCAAGGA-3′), CYP11B2 
(5′-TTGCACCAGGTGGAGAGTATG-3′ and 5′-GTCGGTTGAGACGC-
CATTCT-3′), and 18S rRNA (5′-CGGCTACCACATCCAAGGAA-3′ and 
5′-GCTGGAATTACCGCGGCT-3′) for normalization. For renin 2, Taq-
Man primer sets were used (Applied Biosystems). Changes in the relative 
gene expression normalized to levels of 18S rRNA were determined using 
the relative cycle threshold method.
Renin genotyping. Genomic DNA isolated from ear tissue of sGCα1–/–F2 
mice was amplified using primers yielding a 543-bp fragment specif-
ic for renin 1c and renin 1d (5′-CGACCCGCAGCATTATCAA-3′ and 
5′-ACTACCGCACAGCCTTCTTCACAT-3′); primers amplifying a 1,100-bp 
fragment specific for renin 2 (5′-GCCAAGGAGAAGAGACTACAT-3′ and 
5′-CGGGCCAAGGCGAATCCA-3′); and primers amplifying a 695-bp frag-
ment of intergenic DNA in the renin 1c locus but not in the renin 1d–renin 2 
locus (5′-CAATACGTGTGGTGTAGTCT-3′ and 5′-AGGTACTGTGTTA-
AGGTGGAG-3′). Combination of these 3 PCR reactions allows identifica-
tion of mice homozygous for renin 1c, homozygous for renin 1d and renin 2, 
or heterozygous (renin 1c/renin 1d and renin 2).
Measurements of plasma aldosterone, plasma Ang II, and blood Na+, K+, and 
BUN. After anesthetizing male WT and sGCα1–/– mice with 2% isoflu-
rane, blood was collected, between 8 and 9 a.m., via closed chest cardiac 
puncture in tubes containing EDTA and immediately placed on ice. After 
centrifugation at 4,000 g for 10 minutes at 4°C, the plasma was isolated 
and stored at –80°C until analysis. Plasma aldosterone and Ang II lev-
els were measured using an aldosterone EIA kit (Enzo Life Sciences) and 
an Ang II ELISA kit (Pheonix Pharmaceuticals), respectively, according 
to the instructions provided by the manufacturer and as described previ-
ously (77, 78). BUN, Na+, and K+ were measured in serum using an Heska 
Spotchem chemistry analyzer at the Center for Comparative Medicine at 
Massachusetts General Hospital, Boston.
Treatment with spironolactone, aliskiren, losartan, or enalapril. The renin 
inhibitor aliskiren (79, 80) was administered at a dose of 200 mg/kg/d by 
gavage once daily for 10 days. For treatment with an aldosterone antag-
onist, mice were implanted with subcutaneous time-release, matrix-
driven delivery pellets (Innovative Research of America) releasing 0.24 
mg/d spironolactone for 7 days (81). Control mice were implanted with 
placebo pellets. Losartan (0.1 mg/kg) was administered intravenously. 
The ACE inhibitor enalapril (82), was added to the drinking water (10 
mg/500 ml) for 3 weeks.
Renal clearance experiments. GFR was measured by inulin clearance as 
previously described (83). Briefly, male WTS6 and sGCα1–/–S6 mice were 
anesthetized by i.p. injection of thiobutabarbital sodium (Inactin, Sigma-
Aldrich, 100–120 mg/kg body weight), and the right jugular vein was 
catheterized for fluid infusion. The left carotid artery was cannulated for 
continuous measurement of MAP and blood sampling, and the bladder 
was cannulated for urine collection. Tritiated inulin (10 μCi/ml; NEN) 
in Ringer solution (in mmol/l: 111 NaCl, 30 NaHCO3, and 4.7 KCl) was 
intravenously infused at 3 μl/min for assessment of GFR. After surgery 
and a 60-minute equilibration period, two 30-minute urine samples were 
collected. Blood samples (30 μl) were taken after each clearance period. 
Plasma and urinary 3H-inulin concentration was measured for calculation 
of GFR. Urine Na+ and K+ concentrations were measured by flame pho-
tometry (type 480 Flame Photometer, Corning Medical and Scientific). 
Blood pressure, urine volume, GFR, ENa, EK, FENa, and FEK were calculated 
by standard methods.
Measurement of vascular reactivity in isolated aortic and mesenteric rings. Male 
WT and sGCα1–/– mice were euthanized with pentobarbital (200 mg/kg, 
i.p.). Krebs-Henseleit physiological salt solution was prepared as previously 
described (84). Two milliliters of ice-cold Krebs solution were injected 
retrograde into the left ventricle, and the thoracic aorta or a mesenteric 
artery was dissected free of connective and adipose tissue and placed in 
ice-cold Krebs-Henseleit physiological salt solution pre-equilibrated with 
95% O2/5% CO2 for 15 minutes. Four rings 2–4 mm in length per mouse 
were taken from the aorta or mesenteric artery. Aortic rings were mounted 
between two tungsten wire hooks and suspended vertically in 10-ml 
organ baths of the myograph (TSE Systems) containing physiological 
salt solution and maintained at 37°C, pH 7.4, in a mixture of 95% O2/5% 
CO2. The rings were equilibrated for 90 minutes at a resting force of 1.0 g, 
with replacement of the bathing solution at 15 minute intervals. Mesen-
teric arteries were mounted onto glass cannulas in a pressure myograph 
(DMT), maintained at 85 mmHg, and perfused as described previously 
(85). The viability of the vessel was confirmed by measurement of stable 
and reproducible responses to the addition of phenylephrine (10−6 mol/l). 
Cumulative concentration-tension response curves to sequential addi-
tion of acetylcholine (10−9 to 10−5 mol/l) were obtained. The integrity of 
the endothelium was confirmed by a reproducible and stable relaxation 
of phenylephrine-precontracted rings by acetylcholine. The results of the 
4 rings studied per mouse were averaged to yield an n = 1 per mouse.
Statistics. All continuous measurements are expressed as mean ± SEM. Sta-
tistical comparisons of MAP between multiple strains of mice (sGCα1–/–S6, 
sGCα1–/–B6, sGCα1–/–F2 mice or mice with different renin allele combina-
tions, including mice homozygous for the B6 renin locus or the S6 renin 
locus, or mice heterozygous for the renin locus) were performed by 1-way 
ANOVA with Bonferroni post-hoc testing. A 2-way ANOVA with Bonferroni 
post-hoc testing was used when comparing gene expression, plasma Ang II 
levels, plasma aldosterone levels, and MAP in multiple groups (WTS6, 
WTB6, sGCα1–/–S6, and sGCα1–/–B6 mice, as well as WT and sGCα1–/– mice 
treated with vehicle or a RAAS inhibitor). When comparing two groups 
(renal clearance studies, MAP), the independent Student’s t test was used. 
The vascular reactivity in aortic rings and mesenteric arteries and the acute 
effect of losartan on MAP were analyzed by repeated-measures ANOVA. In 
all cases, a P value less than 0.05 was considered statistically significant.
Study approval. Housing and procedures involving experimental ani-
mals (mice) were approved by the Subcommittee on Research Animal 
Care of Massachusetts General Hospital, the Institutional Animal Care 
and Use Committee, Yale University, and the Animal Ethical Committee 
of Ghent University.
Acknowledgments
This work was supported by Scientist Development Grant 
10SDG2610313 from the American Heart Association (to E.S. 
Buys), an Eleanor and Miles Shore 50th Anniversary Fellowship 
program for Scholars in Medicine from Harvard Medical School 
(to E.S. Buys), the Resuscitation Fellowship Award from the Amer-
ican Heart Association and Philips (to P.Y. Sips), a postdoctoral 
fellowship from CAPES/National Institute of Science and Tech-
research article
2324 The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 6   June 2012
nology in Nanobiopharmaceutics-UFMG (to M.D.G. Rodrigues-
Machado), Fellow-to-Faculty Transition Award 11FTF7290032 
from the American Heart Association (to R. Malhotra), the George 
M. O’Brien Kidney Center at Yale, Core B (to T. Wang), grants 
from the FWO-Vlaanderen and the UGent-GOA programs (to K. 
Decaluwé, J. Van de Voorde, and P. Brouckaert), and NHLBI grant 
R01 HL74352 (to K.D. Bloch) and a grant from the Fondation 
Leducq (to K.D. Bloch).
Received for publication July 21, 2011, and accepted in revised 
form March 21, 2012.
Address correspondence to: Emmanuel Buys, Anesthesia Center 
for Critical Care Research, Department of Anesthesia, Critical 
Care, and Pain Medicine, Massachusetts General Hospital, 55 Fruit 
Street, Thier 511B, Boston, Massachusetts 02114, USA. Phone: 
617.643.3493; Fax: 617.724.7768; E-mail: Ebuys@partners.org.
 1. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, 
Sorlie P. The burden of adult hypertension in the 
United States 1999 to 2000: a rising tide. Hyperten-
sion. 2004;44(4):398–404.
 2. Kung H-C, Hoyert DL, Xu J, Murphy SL. Deaths: final 
data for 2005. Natl Vital Stat Rep. 2008;56(10):1–120.
 3. Newton-Cheh C, et al. Genome-wide association 
study identifies eight loci associated with blood 
pressure. Nat Genet. 2009;41(6):666–676.
 4. Newton-Cheh C, et al. Association of common 
variants in NPPA and NPPB with circulating natri-
uretic peptides and blood pressure. Nat Genet. 2009; 
41(3):348–353.
 5. Conen D, Cheng S, Steiner LL, Buring JE, Ridker 
PM, Zee RY. Association of 77 polymorphisms in 
52 candidate genes with blood pressure progression 
and incident hypertension: the Women’s Genome 
Health Study. J Hypertens. 2009;27(3):476–483.
 6. Kato N, et al. Meta-analysis of genome-wide asso-
ciation studies identifies common variants associ-
ated with blood pressure variation in east Asians. 
Nat Genet. 2011;43(6):531–538.
 7. Ehret GB, et al. Genetic variants in novel pathways 
influence blood pressure and cardiovascular dis-
ease risk. Nature. 2011;478(7367):103–109.
 8. Johnson AD, et al. Association of hypertension drug 
target genes with blood pressure and hypertension in 
86,588 individuals. Hypertension. 2011;57(5):903–910.
 9. Ruilope LM. Hypertension in 2010: blood pressure 
and the kidney. Nat Rev Nephrol. 2011;7(2):73–74.
 10. Mendelsohn ME. In hypertension, the kidney is 
not always the heart of the matter. J Clin Invest. 
2005;115(4):840–844.
 11. Michael SK, et al. High blood pressure arising from 
a defect in vascular function. Proc Natl Acad Sci U S A. 
2008;105(18):6702–6707.
 12. Rees DD, Palmer RM, Moncada S. Role of endo-
thelium-derived nitric oxide in the regulation 
of blood pressure. Proc Natl Acad Sci U S A. 1989; 
86(9):3375–3378.
 13. Huang PL, et al. Hypertension in mice lacking the 
gene for endothelial nitric oxide synthase. Nature. 
1995;377(6546):239–242.
 14. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. 
Abnormal endothelium-dependent vascular relax-
ation in patients with essential hypertension. 
N Engl J Med. 1990;323(1):22–27.
 15. Friebe A, Mergia E, Dangel O, Lange A, Koesling D. 
Fatal gastrointestinal obstruction and hypertension 
in mice lacking nitric oxide-sensitive guanylyl cyclase. 
Proc Natl Acad Sci U S A. 2007;104(18):7699–7704.
 16. Russwurm M, Behrends S, Harteneck C, Koesling 
D. Functional properties of a naturally occurring 
isoform of soluble guanylyl cyclase. Biochem J. 1998; 
335(pt 1):125–130.
 17. Mergia E, Russwurm M, Zoidl G, Koesling D. Major 
occurrence of the new alpha(2)beta(1) isoform of 
NO-sensitive guanylyl cyclase in brain. Cell Signal. 
2003;15(2):189–195.
 18. Buys ES, et al. Gender-specific hypertension and 
responsiveness to nitric oxide in sGC{alpha}1 
knockout mice. Cardiovasc Res. 2008;79(1):179–186.
 19. Nimmegeers S, Sips P, Buys E, Brouckaert P, Van 
de Voorde J. Functional role of the soluble guanylyl 
cyclase alpha(1) subunit in vascular smooth muscle 
relaxation. Cardiovasc Res. 2007;76(1):149–159.
 20. Sips PY, Brouckaert P, Ichinose F. The alpha1 iso-
form of soluble guanylate cyclase regulates cardiac 
contractility but is not required for ischemic precon-
ditioning. Basic Res Cardiol. 2011;106(4):635–643.
 21. Buys ES, et al. sGC(alpha)1(beta)1 attenuates car-
diac dysfunction and mortality in murine inflam-
matory shock models. Am J Physiol Heart Circ Physiol. 
2009;297(2):H654–H663.
 22. Rapp JP, Wang SM, Dene H. A genetic polymorphism 
in the renin gene of Dahl rats cosegregates with 
blood pressure. Science. 1989;243(4890):542–544.
 23. Piccini N, Knopf JL, Gross KW. A DNA polymor-
phism, consistent with gene duplication, correlates 
with high renin levels in the mouse submaxillary 
gland. Cell. 1982;30(1):205–213.
 24. Dickinson DP, Gross KW, Piccini N, Wilson CM. 
Evolution and variation of renin genes in mice. 
Genetics. 1984;108(3):651–667.
 25. Field LJ, Gross KW. Ren-1 and Ren-2 loci are expressed 
in mouse kidney. Proc Natl Acad Sci U S A. 1985; 
82(18):6196–6200.
 26. Vanneste G, Dhaese I, Sips P, Buys E, Brouckaert 
P, Lefebvre RA. Gastric motility in soluble guanyl-
ate cyclase alpha 1 knock-out mice. J Physiol. 2007; 
584(pt 3):907–920.
 27. Atochin DN, et al. Soluble guanylate cyclase alpha-
1beta1 limits stroke size and attenuates neurologi-
cal injury. Stroke. 2010;41(8):1815–1819.
 28. Levy D, et al. Genome-wide association study of 
blood pressure and hypertension. Nat Genet. 2009; 
41(6):677–687.
 29. Azam M, Gupta G, Chen W, Wellington S, Warbur-
ton D, Danziger RS. Genetic mapping of soluble 
guanylyl cyclase genes: implications for linkage to 
blood pressure in the Dahl rat. Hypertension. 1998; 
32(1):149–154.
 30. Hilbert P, et al. Chromosomal mapping of two 
genetic loci associated with blood-pressure regula-
tion in hereditary hypertensive rats. Nature. 1991; 
353(6344):521–529.
 31. Jacob HJ, et al. Genetic mapping of a gene causing 
hypertension in the stroke-prone spontaneously 
hypertensive rat. Cell. 1991;67(1):213–224.
 32. Deng Y, Rapp JP. Cosegregation of blood pressure 
with angiotensin converting enzyme and atrial 
natriuretic peptide receptor genes using Dahl salt-
sensitive rats. Nat Genet. 1992;1(4):267–272.
 33. Wade CM, Daly MJ. Genetic variation in laboratory 
mice. Nat Genet. 2005;37(11):1175–1180.
 34. Hoit BD, et al. Naturally occurring variation in 
cardiovascular traits among inbred mouse strains. 
Genomics. 2002;79(5):679–685.
 35. Gurley SB, et al. Altered blood pressure responses 
and normal cardiac phenotype in ACE2-null mice. 
J Clin Invest. 2006;116(8):2218–2225.
 36. Lum C, Shesely EG, Potter DL, Beierwaltes WH. Car-
diovascular and renal phenotype in mice with one or 
two renin genes. Hypertension. 2004;43(1):79–86.
 37. Salzler HR, et al. Hypertension and albuminuria in 
chronic kidney disease mapped to a mouse chromo-
some 11 locus. Kidney Int. 2007;72(10):1226–1232.
 38. Deng AY, Dene H, Rapp JP. Mapping of a quantita-
tive trait locus for blood pressure on rat chromo-
some 2. J Clin Invest. 1994;94(1):431–436.
 39. Pravenec M, et al. Mapping of quantitative trait loci 
for blood pressure and cardiac mass in the rat by 
genome scanning of recombinant inbred strains. 
J Clin Invest. 1995;96(4):1973–1978.
 40. Wright FA, et al. Genome scan for blood pressure 
loci in mice. Hypertension. 1999;34(4 pt 1):625–630.
 41. Rapp JP. Genetic analysis of inherited hypertension 
in the rat. Physiol Rev. 2000;80(1):135–172.
 42. Stoll M, et al. New target regions for human hyper-
tension via comparative genomics. Genome Res. 2000; 
10(4):473–482.
 43. Moore N, et al. Renin gene polymorphisms and 
haplotypes, blood pressure, and responses to renin-
angiotensin system inhibition. Hypertension. 2007; 
50(2):340–347.
 44. Ehret GB, O’Connor AA, Weder A, Cooper RS, 
Chakravarti A. Follow-up of a major linkage peak 
on chromosome 1 reveals suggestive QTLs associ-
ated with essential hypertension: GenNet study. 
Eur J Hum Genet. 2009;17(12):1650–1657.
 45. Kobori H, Nangaku M, Navar LG, Nishiyama A. The 
intrarenal renin-angiotensin system: from physiol-
ogy to the pathobiology of hypertension and kidney 
disease. Pharmacol Rev. 2007;59(3):251–287.
 46. Peters J, Munter K, Bader M, Hackenthal E, Mullins 
JJ, Ganten D. Increased adrenal renin in transgenic 
hypertensive rats, TGR(mREN2)27, and its regula-
tion by cAMP, angiotensin II, and calcium. J Clin 
Invest. 1993;91(3):742–747.
 47. Jacke K, Witte K, Lemmer B. Mechanisms involved 
in the blunted nitric oxide-cGMP pathway in 
hypertensive TGR(mREN2)27 rats. Eur J Pharmacol. 
2001;415(1):27–30.
 48. Campbell DJ, Valentijn AJ, Condron R. Purification 
and amino-terminal sequence of rat kidney renin: 
evidence for a two-chain structure. J Hypertens. 1991; 
9(1):29–33.
 49. Inagami T. Structure and function of renin. J Hyper-
tens Suppl. 1989;7(2):S3–S8.
 50. Brunner H, et al. Endothelial function and dysfunc-
tion. Part II: association with cardiovascular risk 
factors and diseases. A statement by the Working 
Group on Endothelins and Endothelial Factors of 
the European Society of Hypertension. J Hypertens. 
2005;23(2):233–246.
 51. Stasch JP, Pacher P, Evgenov OV. Soluble gua-
nylate cyclase as an emerging therapeutic target 
in cardiopulmonary disease. Circulation. 2011; 
123(20):2263–2273.
 52. Wagner C, Kurtz A. Regulation of renal renin release. 
Curr Opin Nephrol Hypertens. 1998;7(4):437–441.
 53. Lu M, Wang X, Wang W. Nitric oxide increas-
es the activity of the apical 70-pS K+ chan-
nel in TAL of rat kidney. Am J Physiol. 1998; 
274(5 pt 2):F946–F950.
 54. Wang WH. The cGMP-dependent protein 
kinase stimulates the basolateral 18-pS K chan-
nel of the rat CCD. Am J Physiol Cell Physiol. 2000; 
278(6):C1212–C1217.
 55. Maron BA, et al. Aldosterone increases oxidant 
stress to impair guanylyl cyclase activity by cys-
teinyl thiol oxidation in vascular smooth muscle 
cells. J Biol Chem. 2009;284(12):7665–7672.
 56. Crowley SD, et al. Distinct roles for the kidney and 
systemic tissues in blood pressure regulation by 
the renin-angiotensin system. J Clin Invest. 2005; 
115(4):1092–1099.
 57. Pentz ES, Lopez ML, Kim HS, Carretero O, Smithies 
O, Gomez RA. Ren1d and Ren2 cooperate to preserve 
homeostasis: evidence from mice expressing GFP in 
place of Ren1d. Physiol Genomics. 2001;6(1):45–55.
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 6   June 2012 2325
 58. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, 
Takeda R, Yamamoto H. Vascular aldosterone. Bio-
synthesis and a link to angiotensin II-induced hyper-
trophy of vascular smooth muscle cells. J Biol Chem. 
1994;269(39):24316–24320.
 59. Jaffe IZ, et al. Placental growth factor mediates 
aldosterone-dependent vascular injury in mice. 
J Clin Invest. 2010;120(11):3891–3900.
 60. Cat AN, Touyz RM. A new look at the renin-angio-
tensin system — focusing on the vascular system. 
Peptides. 2011;32(10):2141–2150.
 61. Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma 
V. Aldosterone induces contraction of the resistance 
arteries in man. Atherosclerosis. 2003;166(2):345–349.
 62. Schmidt BM, et al. Rapid nongenomic effects of 
aldosterone on human forearm vasculature. Hyper-
tension. 2003;42(2):156–160.
 63. Meurer S, et al. Nitric oxide-independent vasodila-
tor rescues heme-oxidized soluble guanylate cyclase 
from proteasomal degradation. Circ Res. 2009; 
105(1):33–41.
 64. Stasch JP, et al. Targeting the heme-oxidized nitric 
oxide receptor for selective vasodilatation of diseased 
blood vessels. J Clin Invest. 2006;116(9):2552–2561.
 65. Reckelhoff JF. Sex steroids, cardiovascular disease, 
and hypertension: unanswered questions and some 
speculations. Hypertension. 2005;45(2):170–174.
 66. Ingelfinger JR, Pratt RE, Roth TP, Dzau VJ. Process-
ing of one-chain to two-chain renin in the mouse 
submandibular gland is influenced by androgen. 
Pediatr Res. 1989;25(4):332–335.
 67. Tronik D, Rougeon F. Thyroxine and testosterone 
transcriptionally regulate renin gene expression in 
the submaxillary gland of normal and transgenic 
mice carrying extra copies of the Ren2 gene. FEBS 
Lett. 1988;234(2):336–340.
 68. Baltatu O, Cayla C, Iliescu R, Andreev D, Jordan C, 
Bader M. Abolition of hypertension-induced end-
organ damage by androgen receptor blockade in 
transgenic rats harboring the mouse ren-2 gene. 
J Am Soc Nephrol. 2002;13(11):2681–2687.
 69. Krege JH, et al. Male-female differences in fertility 
and blood pressure in ACE-deficient mice. Nature. 
1995;375(6527):146–148.
 70. O’Donnell CJ, et al. Evidence for association and 
genetic linkage of the angiotensin-converting 
enzyme locus with hypertension and blood pressure 
in men but not women in the Framingham Heart 
Study. Circulation. 1998;97(18):1766–1772.
 71. Evgenov OV, Pacher P, Schmidt PM, Hasko G, 
Schmidt HH, Stasch JP. NO-independent stimu-
lators and activators of soluble guanylate cyclase: 
discovery and therapeutic potential. Nat Rev Drug 
Discov. 2006;5(9):755–768.
 72. Stasch JP, Dembowsky K, Perzborn E, Stahl E, 
Schramm M. Cardiovascular actions of a novel NO-
independent guanylyl cyclase stimulator, BAY 41-8543: 
in vivo studies. Br J Pharmacol. 2002;135(2):344–355.
 73. Brandes RP, et al. Increased nitrovasodilator sensi-
tivity in endothelial nitric oxide synthase knockout 
mice: role of soluble guanylyl cyclase. Hypertension. 
2000;35(1 pt 2):231–236.
 74. Kruglyak L, Lander ES. A nonparametric approach 
for mapping quantitative trait loci. Genetics. 1995; 
139(3):1421–1428.
 75. Lander E, Kruglyak L. Genetic dissection of com-
plex traits: guidelines for interpreting and report-
ing linkage results. Nat Genet. 1995;11(3):241–247.
 76. Lander ES, Botstein D. Mapping mendelian factors 
underlying quantitative traits using RFLP linkage 
maps. Genetics. 1989;121(1):185–199.
 77. Aoyagi T, et al. Vasopressin regulates the renin-
angiotensin-aldosterone system via V1a receptors 
in macula densa cells. Am J Physiol Renal Physiol. 
2008;295(1):F100–F107.
 78. Kapur NK, et al. Hemodynamic modulation of 
endocardial thromboresistance. Circulation. 2007; 
115(1):67–75.
 79. Brown MJ.  Aliskiren.  Circulation .  2008; 
118(7):773–784.
 80. Jensen C, Herold P, Brunner HR. Aliskiren: the first 
renin inhibitor for clinical treatment. Nat Rev Drug 
Discov. 2008;7(5):399–410.
 81. Williams JS. Hypertension: spironolactone 
and resistant hypertension. Nat Rev Endocrinol. 
2010;6(5):248–250.
 82. Jacke K, Witte K, Huser L, Behrends S, Lemmer B. Con-
tribution of the renin-angiotensin system to subsensi-
tivity of soluble guanylyl cyclase in TGR(mREN2)27 
rats. Eur J Pharmacol. 2000;403(1–2):27–35.
 83. Wang T, Inglis FM, Kalb RG. Defective fluid and 
HCO(3)(–) absorption in proximal tubule of 
neuronal nitric oxide synthase-knockout mice. Am 
J Physiol Renal Physiol. 2000;279(3):F518–F524.
 84. Yu B, et al. Endothelial dysfunction enhances vaso-
constriction due to scavenging of nitric oxide by 
a hemoglobin-based oxygen carrier. Anesthesiology. 
2010;112(3):586–594.
 85. Atochin DN, et al. The phosphorylation state of 
eNOS modulates vascular reactivity and outcome 
of cerebral ischemia in vivo. J Clin Invest. 2007; 
117(7):1961–1967.
